Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 869-873

  Suzuki, Fumitaka ^a,b   Sezaki, Hitomi ^a   Akuta, Norio ^a   Suzuki, Yoshiyuki ^a   Kawamura, Yusuke ^a   Hosaka, Tetsuya ^a   Kobayashi, Masahiro ^a   Saitoh, Satoshi ^a   Arase, Yasuji ^a   Ikeda, Kenji ^a   Kobayashi, Mariko ^a   Watahiki, Sachiyo ^a   Mineta, Rie ^a   Suzuki, Yukiko ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

^b Okinaka Memorial Institute for Medical Research   (Japan)

Author keywords

Hepatitis B virus; Resistant

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; AMINO ACID; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; TENOFOVIR DISOPROXIL; VIRUS DNA; ADENINE; ANTIVIRUS AGENT; GUANINE; PHOSPHONIC ACID DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID SUBSTITUTION; ARTICLE; CASE REPORT; DRUG SENSITIVITY; EUROPE; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LAPAROSCOPY; LIVER CIRRHOSIS; MONOTHERAPY; NUCLEOTIDE SEQUENCE; PATIENT COMPLIANCE; UNITED STATES; VIRUS STRAIN; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; BLOOD; DRUG COMBINATION; GENETICS; HEPATITIS B, CHRONIC; ISOLATION AND PURIFICATION; MIDDLE AGED; TREATMENT OUTCOME; VIROLOGY;

ADENINE; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MIDDLE AGED; ORGANOPHOSPHONATES; TREATMENT OUTCOME;

EID: 84903614328     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S65349     Document Type: Article

References (23)

1. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet. 1981;2(8256):1129-1133.
2. Suzuki F, Suzuki Y, Tsubota A, et al. Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy. J Hepatol. 2002;37(6):824-830.
3. Marcellin P, Chang TT, Lim SG, et al; Adefovir Dipivoxil 437 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigenpositive chronic hepatitis B. N Engl J Med. 2003;348(9):808-816.
4. Ono A, Suzuki F, Kawamura Y, et al. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients. J Hepatol. 2012;57(3):508-514.
5. Suzuki F, Arase Y, Suzuki Y, et al. Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan. J Gastroenterol. 2012;47(7):814-822.
6. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009;137(5):1593-1608.
7. Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WE. Crossresistance testing of next-generation nucleoside and nucleotide ana- logues against lamivudine-resistant HBV. Antivir Ther. 2005;10(5): 625-633.
8. Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2011;140(1):132-143.
9. Snow-Lampart A, Chappell B, Curtis M, et al. No resistance to teno- fovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology. 2011;53(3):763-773.
10. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381(9865): 468-475.
11. Gordon SC, Krastev Z, Horban A, et al. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology. 2013;58(2):505-513.
12. Kitrinos KM, Corsa A, Liu Y, et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology. 2014;59(2):434-442.
13. van Bömmel F, de Man RA, Wedemeyer H, et al. Long-term effi- cacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology. 2010;51(1):73-80.
14. Suzuki F, Akuta N, Suzuki Y, et al. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudineresistant hepatitis B virus mutants. J Med Virol. 2006;78(3): 341-352.
15. Sheldon J, Camino N, Rodés B, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther. 2005;10(6):727-734.
16. Delaney WE, Ray AS, Yang H, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother. 2006;50(7):2471-2477.
17. Qi X, Xiong S, Yang H, Miller M, Delaney WE. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther. 2007;12(3):355-362.
18. Qin B, Budeus B, Cao L, et al. The amino acid substitutions rtP177G and rtF249A in the reverse transcriptase domain of hepatitis B virus polymerase reduce the susceptibility to tenofovir. Antiviral Res. 2013;97(2):93-100.
19. Petersen J, Ratziu V, Buti M, et al. Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. J Hepatol. 2012;56(3):520-526.
20. Kim YJ, Sinn DH, Gwak GY, et al. Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures. World J Gastroenterol. 2012;18(47):6996-7002.
21. Seto WK, Liu K, Wong DK, et al. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. J Hepatol. 2013;59(4):709-716.
22. Karatayli E, Idilman R, Karatayli SC, et al. Clonal analysis of the quasispecies of antiviral-resistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir. Antivir Ther. 2013;18(1):77-85.
23. Okamoto H, Tsuda F, Sakugawa H, et al. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol. 1988;69(10):2575-2583.